Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Oliver Sartor MD

Oliver Sartor MD

Director of the Radiopharmaceutical Trials, Chief of the Genitourinary Cancer Malignancy Group, Mayo Clinic, Rochester, Minnesota

Dr. Oliver Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 500 peer-reviewed articles, led or co-led multiple national and international clinical studies, including four phase III studies pivotal for FDA approval (Quadramet, Xofigo, Pluvicto, and Jevtana). He has lectured widely, and at last count has given invited lectures in 33 countries.

He has served as the past Chairman of the Department of Defense Prostate Cancer Integration Panel, is past Editor-in-Chief of the peer-reviewed journal Clinical Genitourinary Cancer, and is the Medical Oncology Chair of the GU committee of NRG, a national cancer research group. He is also a past member of the National Cancer Institute Board of Scientific Counselors (Clinical Sciences and Epidemiology).

Disclosures

CONSULTANT: Advanced Accelerator Applications (AAA), Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics, Inc., Bavarian Nordic, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis, Constellation, Dendreon, EMD Serono, Fusion, Isotopen Technologien Meunchen, Janssen, Merck, Moyvant, Myriad, Noria Therapeutics, Inc., Novartis, Noxopharm, Progenics, POINT Biopharma, Pfizer, Sanofi, Tenebio, Telix, Theragnostics.

Grant/Research Support: Advanced Accelerator Applications, Amgen, AstraZeneca, Bayer, Constellation, Endocyte, Invitae, Janssen, Lantheus, Merck, Progenics, Tenebio.

 

Recent Contributions to PracticeUpdate:

  1. Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Metastatic Prostate Cancer
  2. LuPSMA Versus Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer
  3. ACIS Trial of Apalutamide and Abiraterone in Chemotherapy-Naive mCRPC
  4. [177Lu]Lu-PSMA-617 vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer
  5. ASCO GU 2021: Recommendations From Dr. Oliver Sartor
  6. Immunotherapy in the Treatment of Prostate Cancer
  7. Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer
  8. Prostate Radiotherapy With Adjuvant ADT Improves Metastasis-Free Survival Over Neoadjuvant ADT
  9. Androgen Deprivation Therapy and Radiotherapy in Intermediate-Risk Prostate Cancer
  10. Quality of Life in Patients With Metastatic Prostate Cancer Following Treatment With Cabazitaxel vs Abiraterone or Enzalutamide

Most Read This Week

Recently Updated